WADA welcomes the decision by the Court of Arbitration for Sport (CAS) to uphold the appeal it filed against the decision of the Finnish appeal board to exonerate cross-country skier Juha Lallukka for an anti-doping rule violation (ADRV) relating to human Growth Hormone (hGH).
The decision to find the athlete had committed a rule violation and sanction the athlete for a period of two years fully answers all the issues raised by the CAS panel in the Andrus Veerpalu case. It also means there is no doubt surrounding the validity and reliability of the recently published version 2 of the Guidelines for the application of the human Growth Hormone (hGH) Isoform Differential Immunoassays for detection of doping with human Growth Hormone in sport.
WADA Director General, David Howman: “WADA is pleased that, in reaching its decision, CAS recognized that all issues raised by the Veerpalu case have now been answered in a “convincing manner”, and that WADA had fully met the burden of proof required for Mr. Lallukka to be sanctioned.
“WADA is glad that the issues relating to hGH testing have been resolved, and continues to encourage all anti-doping organizations to analyze samples as part of their regular anti-doping program.”